EA200970449A1 - Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность - Google Patents

Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность

Info

Publication number
EA200970449A1
EA200970449A1 EA200970449A EA200970449A EA200970449A1 EA 200970449 A1 EA200970449 A1 EA 200970449A1 EA 200970449 A EA200970449 A EA 200970449A EA 200970449 A EA200970449 A EA 200970449A EA 200970449 A1 EA200970449 A1 EA 200970449A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acetaminophen
compositions
result
side effects
including reduced
Prior art date
Application number
EA200970449A
Other languages
English (en)
Russian (ru)
Inventor
Эрик М. Содерлинг
Original Assignee
Эрик М. Содерлинг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эрик М. Содерлинг filed Critical Эрик М. Содерлинг
Publication of EA200970449A1 publication Critical patent/EA200970449A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200970449A 2006-12-09 2007-12-08 Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность EA200970449A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87374306P 2006-12-09 2006-12-09
US11/952,556 US20080139654A1 (en) 2006-12-09 2007-12-07 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
PCT/US2007/025167 WO2008073344A1 (en) 2006-12-09 2007-12-08 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Publications (1)

Publication Number Publication Date
EA200970449A1 true EA200970449A1 (ru) 2009-08-28

Family

ID=39498949

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970449A EA200970449A1 (ru) 2006-12-09 2007-12-08 Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность

Country Status (13)

Country Link
US (1) US20080139654A1 (enExample)
EP (1) EP2094253A4 (enExample)
JP (1) JP2010513229A (enExample)
KR (1) KR20090089867A (enExample)
CN (1) CN101588797A (enExample)
AU (1) AU2007332812A1 (enExample)
BR (1) BRPI0721216A2 (enExample)
CA (1) CA2671490A1 (enExample)
EA (1) EA200970449A1 (enExample)
IL (1) IL199056A0 (enExample)
MX (1) MX2009006177A (enExample)
WO (1) WO2008073344A1 (enExample)
ZA (1) ZA200904764B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080187A1 (it) * 2008-02-07 2009-08-08 Velleja Res Srl Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
CN102573463A (zh) * 2009-07-15 2012-07-11 小利兰·斯坦福大学托管委员会 N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法
TR201007652A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Sinerjik etki.
US20140235730A1 (en) * 2011-09-23 2014-08-21 Gavis Pharmaceuticals, Llc Solid, edible, chewable laxative composition
WO2014159994A1 (en) * 2013-03-13 2014-10-02 Nbip, Llc Compositions and methods for removing the odor from glutathione when mixed in an aqueous system
US10104882B2 (en) * 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
JP7311267B2 (ja) * 2016-01-11 2023-07-19 エゲティス・セラピューティクス・アーベー 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
KR101962518B1 (ko) 2016-09-13 2019-03-26 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물
WO2018089400A1 (en) * 2016-11-09 2018-05-17 The Feinstein Institute For Medical Research Iguratimod as an mif inhibitor
KR102813413B1 (ko) 2019-08-27 2025-05-27 주식회사 엘지에너지솔루션 단위셀의 두께측정장치 및 두께측정방법
US11590090B2 (en) 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GR1002731B (el) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Also Published As

Publication number Publication date
MX2009006177A (es) 2009-08-31
WO2008073344A1 (en) 2008-06-19
ZA200904764B (en) 2012-12-27
EP2094253A4 (en) 2010-02-10
BRPI0721216A2 (pt) 2014-12-02
AU2007332812A1 (en) 2008-06-19
US20080139654A1 (en) 2008-06-12
EP2094253A1 (en) 2009-09-02
CA2671490A1 (en) 2008-06-19
KR20090089867A (ko) 2009-08-24
IL199056A0 (en) 2010-03-28
CN101588797A (zh) 2009-11-25
JP2010513229A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
MX2009006177A (es) Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida.
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
CR10636A (es) Inhibidor de quinasa
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
WO2007134086A3 (en) Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
BRPI0509184A (pt) composições farmacêuticas
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA201070786A1 (ru) Бензофуропиримидиноны
FR2883179B1 (fr) Comprime enrobe
TNSN08417A1 (en) Inhibitors of 11-beta- hydroxysteroid dehydrogenase 1
WO2007098270A3 (en) Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
MXPA05012463A (es) Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
DE602007014036D1 (de) 12-aryl-prostaglandin-analoga
DE602007005372D1 (de) Zweischichtige tablette zur verhinderung von kardiovaskulären ereignissen
CL2017000669A1 (es) Forma de dosificación farmacéutica (divisional de la solicitud 1029/2014)
WO2007008684A3 (en) Ligands of melanocortin receptors
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200738649A (en) Calcilytic compounds
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
NO20091771L (no) Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat